In this textbased activity leading experts discuss the current therapeutic landscape for advanced EGFRmutated NSCLC unmet needs in the progressive disease setting and the promise of novel investigational agents targeting HER3
- Provider:Clinical Care Options
- Activity Link: https://clinicaloptions.com/CE-CME/oncology/novel-her3-agents-for-egfr-mutated-nsclc-2/26497-68584
- Start Date: 2024-12-17 06:00:00
- End Date: 2024-12-17 06:00:00
- Credit Details: AMA PRA Category 1 Credit™️: 0.75 hours
- Commercial Support: Source: Daiichi Sankyo, Inc. - Amount: 65140.0 - Is Kind Support: False
- Activity Type: Enduring Material
- CME Finder Type: Online Learning
- Fee to Participate: No, it's free
- Measured Outcome: Learner Knowledge, Learner/Team Competence
- Provider Ship: Directly Provided
- Registration: Open to all
Subscribe
Login
0 Comments
Oldest